However, sometimes the yolk sac can persist between the amniotic and chorionic membranes even after the 12th week of pregnancy ends. Most persistent yolk sac cases that have been reported in the literature were anecdotal, and to the best of our knowledge, no clinical study has ever focused on a persistent yolk sac, and no systematic study has been conducted to specify its clinical importance.
This study aimed to determine the frequency and clinical importance of a persistent yolk sac in pregnancies at 12 to 13 weeks. That is, the purpose of this study was to investigate whether a persistent yolk sac is associated with adverse perinatal outcomes, including abnormal sonographic findings, isolated structural defects, poor obstetric outcomes, and perinatal mortality.
Materials and Methods
This prospective study was approved by the Institutional Review Board and Ethical Committee of Ankara Atatürk Research and Education Hospital, where the study was conducted. The study reviewed a total of 324 women who had normal singleton pregnancies with a gestational age of 12 weeks to 13 weeks 6 days and who were consecutively admitted to the study center for first-trimester screening (for chromosomal abnormalities) between April 2010 and February 2011. Written informed consent was obtained from each participant before the study was started.
The recruited women were sonographically examined using LOGIQ 9 sonographic equipment (GE Healthcare, Milwaukee, WI). The sonographic examination was preferably performed transabdominally with a 3-to 5-MHz convex probe. However, a transvaginal sonographic examination was accomplished with a 5-to 8-MHz endocavitary probe in 94 patients (29%) for several factors, including obesity, anatomic inconvenience, and a persistent fetal position preventing measurement of nuchal translucency. 11 All of the sonographic examinations were performed by 1 of 2 radiologists (S.T. or Y.A.) who were experienced in obstetric sonography. During the sonographic examination, the gestational age was specified by measurement of the crown-rump length, 12 and then the examiner investigated whether there were any major fetal abnormalities. Afterward, the presence or absence of the yolk sac in the extra-amniotic area was carefully assessed.
The yolk sac size was measured by placing the calipers on the inner limits of the longest diameter of the yolk sac on a magnified scan. It was noted that the calipers would have accuracy of 0.1 mm. It has been well established that the yolk sac begins to diminish in size physiologically after the 10th or 11th week of gestation. Accordingly, this process can be identified on serial sonographic scans (Figure 1) .
A persistent yolk sac has been defined as a yolk sac that achieves a diameter of 5.6 mm or greater without losing its internal pressure at the 12th week of pregnancy or later (Figures 2 and 3) . The reason for this value is that the upper limit of the yolk sac diameter has been reported to be 5.6 mm for pregnancies at 5 to 10 weeks in a previously published study. 2 Therefore, a yolk sac with a diameter of less than 5.6 mm and irregular external contours (ie, with partially or mostly reduced internal pressure) was regarded as having undergone regression. The images with a persistent yolk sac were recorded digitally on the local sonographic device.
A second-trimester sonographic examination was scheduled in all of the recruited women so that any fetal structural abnormality could be excluded. Data on pregnancy outcomes were obtained from the medical records of the study center for the pregnant women who delivered there. As for the women who delivered outside the study center, patient contact was provided by telephone calls, and necessary information was acquired. Because 42 women (13.0%) were lost to follow-up, a total of 282 pregnancies were enrolled for the final analysis. Approximately 68% of these pregnancies (n = 192) were assessed transabdominally, and 32% of them (n = 90) were examined via the transvaginal route at 12 and 13 weeks' gestation. An adverse perinatal outcome was defined as either perinatal morbidity (indicating abnormal sonographic findings, isolated structural defects, polyhydramnios, oligohydramnios, preeclampsia, gestational diabetes, preterm delivery, and respiratory distress syndrome) or perinatal death (spontaneous miscarriage, intrauterine death, and neonatal death). 13 The neonates born to the study population were assessed by pediatricians who performed a complete physical examination and baseline blood tests, including a complete blood count, biochemical analysis, and thyroid function tests.
Collected data were analyzed with the SPSS version 16.0 software (SPSS Inc, Chicago, IL) on computerized media. The numeric variables were expressed as either mean ± standard deviation or number (percent), where appropriate. To compare pregnancies at 12 and 13 weeks with respect to a persistent yolk sac, the χ2 test was used. Two-tailed P < .05 was accepted as statistically significant.
Results
This study reviewed 162 women who had healthy singleton pregnancies at 12 weeks and 120 women who had healthy singleton pregnancies at 13 weeks, thus making a total of 282 pregnant women. The demographic and clinical characteristics of the women are listed in Table 1 .
A persistent yolk sac was detected by sonography in 25 pregnancies. The average diameter of the persistent yolk sacs was 6.3 ± 0.2 mm (range, 5.6-8.0 mm). As shown in Table 2 , a persistent yolk sac was noted in 15.5% of the pregnancies that were examined via the transvaginal route (14 of 90) and in 5.7% of the pregnancies that were evaluated by transabdominal sonography (11 of 192) . Moreover, the frequency of a persistent yolk sac at 12 weeks' gestation was significantly higher than at 13 weeks (P = .017).
Regression of the yolk sac was observed on sonography in 67 pregnancies. The average reduction in the yolk sac diameter was 3.7 ± 1.5 mm (range, 1.4-5.5 mm). Regression of the yolk sac was seen in 46.6% of the pregnancies that were examined via the transvaginal route (42 of 90) and in 13% of the pregnancies that were evaluated by transabdominal sonography (25 of 192; Table 2 ). In addition, regression of the yolk sac was significantly more frequent at the 12th week of pregnancy compared with the 13th week of pregnancy (P = .02).
In this study, 13 weeks 4 days corresponded to the most advanced gestational age at which a persistent yolk sac was visualized. Thus, a yolk sac was unobserved in 28 pregnancies with gestational ages exceeding 13 weeks 4 days. On the other hand, regression of the yolk sac was detected in 1 pregnancy with a gestational age of 13 weeks 5 days and in 2 pregnancies with a gestational age of 13 weeks 6 days. Table 3 shows the adverse pregnancy outcomes (depicted as perinatal morbidity and mortality) associated with persistence of the yolk sac. As shown in Table 3 , a persistent yolk sac was not associated with adverse perinatal outcomes, including abnormal sonographic findings, isolated structural defects, poor obstetric outcomes, and perinatal mortality. All 25 pregnancies with a persistent yolk sac had normal blood count and serum biochemistry results. Serum β-human chorionic gonadotropin and pregnancy-associated plasma protein A concentrations in these pregnancies were also found to be within the normal range. Only 1 of these pregnancies with a persistent yolk sac had low levels of thyroid-stimulating hormone and high levels of thyroxine.
Discussion
Previously conducted studies have claimed that the yolk sac begins to diminish in size toward the end of the first gestational trimester and eventually disappears. [6] [7] [8] Similarly, in our study, the yolk sac was absent in 81.2% and regressed in 13% of the pregnancies that were visualized by transab- dominal sonography. On the other hand, the absence and regression of the yolk sac were determined in, respectively, 37.8% and 46.6% of the pregnancies that were assessed transvaginally. However, there were yolk sacs with nondeformed margins, diameters of 5.6 mm or greater, and preserved internal pressure (ie, the yolk sac was persistent) in 5.7% of the pregnancies that were evaluated by transabdominal sonography and in 15.5% of the pregnancies that were assessed by transvaginal sonography. This finding suggests that a persistent yolk sac or even a gradually enlarging yolk sac may be observed in some pregnancies at the end of the first trimester. It is unknown whether such a situation has clinical importance. To the best of our knowledge, no clinical trial aiming to clarify the prognostic importance of a persistent yolk sac has yet been published. Despite the lack of reliable and accurate data about persistent yolk sacs, the current literature contains several welldesigned studies that have a major emphasis on the clinical importance of abnormally large yolk sacs in the embryonic period. One of these studies was conducted by Lindsay et al, 2 who consecutively examined 486 women before 10 weeks' gestation. It was reported that a yolk sac diameter of greater than 2 SDs above the mean, when compared with the mean gestational sac diameter, allowed the prediction of an abnormal pregnancy outcome with sensitivity of 15.6%, specificity of 97.4%, and a positive predictive value of 60.0%, whereas a yolk sac diameter of greater than 2 SDs below the mean predicted an abnormal outcome with sensitivity of 15.6%, specificity of 95.3%, and a positive predictive value of 44.4%. No pregnancy with a normal outcome had a yolk sac diameter of greater than 5.6 mm. The yolk sac diameter exceeded 5.6 mm in 6 patients for whom the gestational outcome was always unfavorable. Subsequently, Lindsay et al 2 concluded that a yolk sac diameter of greater than 5.6 mm was strongly related to a poor obstetric prognosis and therefore deserved close surveillance.
The other study concerned with abnormally large yolk sacs was performed in a cohort of 175 pregnancies that were assessed by Berdahl et al. 9 It was reported that a yolk sac diameter of greater than 5 mm indicated a 3-fold increased risk for first-trimester loss, independent of maternal risk factors such as age, body mass index, polycystic ovary syndrome, smoking, and diabetes. In addition, that study was the first to show that an enlarged yolk sac diameter may be related to an enhanced risk of preterm delivery.
The aforementioned studies indicated the clinical importance of an abnormal yolk sac size during the embryonic period. However, the findings of our study revealed that a large yolk sac detected toward the end of the first trimester was not associated with adverse gestational outcomes.
The general attitude of the study center is to adopt a transabdominal approach in screening for chromosomal abnormalities during the first trimester of pregnancy, and the transvaginal route is only preferred in cases in which anatomic details cannot be observed because of obesity or an appropriate position for the measurement of nuchal translucency cannot be achieved. In our study, the detection rate for a persistent or regressed yolk sac was significantly higher in pregnancies assessed by the transvaginal approach. This finding can be attributed to the fact that transvaginal sonography uses high-frequency probes, which are capable of visualizing the anatomic details. If the recruited pregnancies that were examined transabdominally had been assessed by the transvaginal route, the detection of persistent and regressed yolk sacs would probably have been more frequent.
There were some limitations to our study. First, the number of participants with a diagnosis of a persistent yolk sac was relatively small. Second, no data were available about the yolk sac size in the participants during the embryonic period. Third, the duration of the persistent yolk sacs was not documented by a longitudinal follow-up.
In conclusion, the yolk sac mostly disappears toward the end of the first trimester. However, it may persist in some pregnancies even to the 13th week of gestation. Although persistence of the yolk sac seems to be unrelated to adverse perinatal outcomes, further longitudinal research is required to understand the clinical importance of a persistent yolk sac.
